Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
May 07,2024
World Cancer Day Focus: AACR Annual Meeting Leads Global New Cancer Drug Trends, Domestic Drugs Lead the Trend
At the AACR annual meeting, many top cancer research experts shared the latest scientific and medical research results. ​What is also eye-catching is that the Medicilon antibody drug conjugate (ADC) R&D service platform demonstrated its strong strength at this annual meeting.
More
World Cancer Day Focus: AACR Annual Meeting Leads Global New Cancer Drug Trends, Domestic Drugs Lead the Trend
May 07,2024
Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs
On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs.
More
Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs
Apr 10,2024
Medicilon (Chuansha) Inc. won the "Development Potential Award" of Chuansha New Town
Medicilon, relied on its outstanding performance and strong development momentum in the field of biopharmaceutical, won the "Development Potential Award" for the 2023 Chuansha New Town Economic Work Advanced Unit.
More
Medicilon (Chuansha) Inc. won the "Development Potential Award" of Chuansha New Town
Apr 10,2024
The 2024 Medicilon Innovative Drug Industry Ecological Collaboration Conference was a complete success
On March 18, the Medicilon Innovation Drug Industry Ecological Collaboration Conference was successfully held. At the conference, Medicilon starts of the globalization and the grand launch of two key technology service platforms.
More
The 2024 Medicilon Innovative Drug Industry Ecological Collaboration Conference was a complete success
Apr 10,2024
Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List
Medicilon won the "2024 Shanghai Hard Core Technology Enterprises TOP100 List" with its hard-core technology and innovative technology service platform in the preclinical field of biopharmaceutical.
More
Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List
Apr 10,2024
Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy
On March 18, Medicilon and Innoforce Pharmaceuticals (Innoforce) reached a strategic collaboration, focusing on cutting-edge fields such as RNA, cell and gene therapy, and work together to open a new chapter in innovative drug research and development.
More
Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy
Mar 19,2024
Medicilon Appoints Dr. Wenjie Li as Vice President of the CMC Unit to Expand our CRDMO Business
Medicilon announced the appointment of Dr. Wenjie Li as Vice President of the CMC Unit. With this appointment, Dr. Wenjie Li will continue to expand and strengthen Medicilon's services in the CRDMO field.
More
Medicilon Appoints Dr. Wenjie Li as Vice President of the CMC Unit to Expand our CRDMO Business
Mar 11,2024
Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout
Medicilon officially appoints Dr. Qingcong Lin as Executive Vice President and President of Medicilon USA Corp, a significant step to deepen its global and strategic layout.
More
Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout
Feb 28,2024
Medicilon 20th Anniversary - Keep pace with the times in innovation, thanks for having you
In 2024, Medicilon will celebrate its 20th anniversary. During the past 20 years, Medicilon has transformed into a leading one-stop biopharmaceutical preclinical R&D service CRO in China, and is moving forward with its goal of being a world-class CRO.
More
Medicilon 20th Anniversary - Keep pace with the times in innovation, thanks for having you
Feb 21,2024
Medicilon won the "Best Strategic Partner" award from NewDEL Biotech in 2023
Shanghai Medicilon Inc. (Medicilon) has recently won the "Best Partner Award" from Gluetacs Therapeutics and the "2003 Best Partner Award" from SicaGene.
More
Medicilon won the "Best Strategic Partner" award from NewDEL Biotech in 2023
Jan 30,2024
Medicilon was selected as the "2023 Shanghai Professional Technical Service Platform"
On January 18, the Science and Technology Commission of Shanghai Municipality released the 2023 Shanghai Professional Technical Service Platform construction project list. There are only 29 platforms in Shanghai on the list. Medicilon Preclinical Research (Shanghai) LLC, a subsidiary of Shanghai Medicilon Inc. (Medicilon), Nucleic Acid Drug R&D Service Platform was successfully selected!
More
Medicilon was selected as the "2023 Shanghai Professional Technical Service Platform"
Jan 30,2024
Gain Client Recognition Again! Medicilon won the 2023 SicaGene "Best Partner Award"
Recently, Shanghai Medicilon Inc. (Medicilon) won the "Best Partner Award" from SicaGene. The strong support provided in collaboration projects has been recognized by client again.
More
Gain Client Recognition Again! Medicilon won the 2023 SicaGene "Best Partner Award"
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->